iiinova — where your digital self keeps evolving

ecmmcandidaiv.bsky.social

@ecmmcandidaiv.bsky.social

36 followers 5 following 6 posts

Posts Replies Media

ecmmcandidaiv.bsky.social @ecmmcandidaiv.bsky.social · 13/04/2026

Excited to share our new publication: Clinical Characteristics, Management and Outcomes of Non-ICU Candidemia – a subanalysis of the ECMM Candida III multinational European cohort study. 😊 academic.oup.com/ofid/article... @martinhoenigl.bsky.social @olivercornely.bsky.social

academic.oup.com

Clinical Characteristics, Management and Outcomes of Nonintensive Care Unit Candidemia: Subanalysis of the ECMM Candida III Multinational European Observational Cohort Study

A subanalysis of 396 candidemia cases diagnosed outside the intensive care unit from the pan-European multicenter ECMM Candida III study showed higher surv

ecmmcandidaiv.bsky.social @ecmmcandidaiv.bsky.social · 13/01/2026

Update on Candida IV study at #TIMM2025 Still open for registration 🔬🧫🧪 Join now!

ecmmcandidaiv.bsky.social @ecmmcandidaiv.bsky.social · 12/01/2026

Preliminary results of the Candida IV study at #ISHAM2025 and #ESCMID2025 Study is still open to join 🔬🥼👩‍🔬

Reposted by @ecmmcandidaiv.bsky.social

Oliver Cornely @olivercornely.bsky.social · 05/12/2025

Early mycological clearance in uncomplicated candidaemia can improve outcomes, reduce ICU stay, and lower healthcare costs. Timely antifungal therapy is key. Read more: doi.org/10.1111/myc.... @martinhoenigl.bsky.social #Candidaemia #AntifungalTherapy #InfectiousDiseases #ICU #Healthcare

The Importance of Early Mycological Clearance of Uncomplicated Candidaemia and Its Implications for Clinical Practice

Invasive candidiasis is a life-threatening infection associated with high morbidity, mortality and healthcare costs in both general and critical care settings. Timely diagnosis and adequate antifunga....

ecmmcandidaiv.bsky.social @ecmmcandidaiv.bsky.social · 23/05/2025

Proud to present the progress of ECMM Candida IV study at #ISHAM2025 Still open for participation! @martinhoenigl.bsky.social

ecmmcandidaiv.bsky.social @ecmmcandidaiv.bsky.social · 24/04/2025

Exciting news! The ECMM Candida IV study is now featured on the ECMM website! Find all the details here: www.ecmm.info/working-grou... @martinhoenigl.bsky.social

Antifungal tolerance, resistance and clinical outcomes on candidemia caused by non-albicans Candida - ECMM

ECMM Candida IV Antifungal tolerance, resistance and clinical outcomes on candidemia caused by non-albicans Candida Observation periods/Timeline Observation period: April 1st, 2024 – September 30th, ...

ecmmcandidaiv.bsky.social @ecmmcandidaiv.bsky.social · 08/04/2025

ECMM Candida IV Study is still open for participation Global study on non-albicans candidemia Requirements: 🔬Clinical data + isolates (no limit per site) 📅Apr 2024-Sep 2025 📦Ship isolates in one batch at study end 💰Case-based reimbursement available @martinhoenigl.bsky.social